H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 26.33 CNY 0.15% Market Closed
Market Cap: 24.3B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Hubei Jumpcan Pharmaceutical Co Ltd

Wall Street analysts forecast Hubei Jumpcan Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Hubei Jumpcan Pharmaceutical Co Ltd is 53.41 CNY with a low forecast of 52.88 CNY and a high forecast of 54.98 CNY.

Lowest Forecast
Wall Street Target
52.88 CNY
101% Upside
Average Forecast
Wall Street Target
53.41 CNY
103% Upside
Highest Forecast
Wall Street Target
54.98 CNY
109% Upside
Lowest
Price Target
52.88 CNY
101% Upside
Average
Price Target
53.41 CNY
103% Upside
Highest
Price Target
54.98 CNY
109% Upside
Hubei Jumpcan Pharmaceutical Co Ltd Competitors:
Price Targets
EYPT
EyePoint Pharmaceuticals Inc
391% Upside
S
GPCR
Structure Therapeutics Inc
197% Upside
TARS
Tarsus Pharmaceuticals Inc
46% Upside
S
002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
31% Downside
EYPT
EyePoint Pharmaceuticals Inc
391% Upside
S
GPCR
Structure Therapeutics Inc
197% Upside
TARS
Tarsus Pharmaceuticals Inc
46% Upside
S
002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
31% Downside
AUROPHARMA
Aurobindo Pharma Ltd
23% Upside
LINCOLN
Lincoln Pharmaceuticals Ltd
85% Upside
600085
Beijing Tongrentang Co Ltd
22% Upside
B
053030
Binex Co Ltd
109% Upside

Revenue
Forecast

Revenue Estimate
Hubei Jumpcan Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 2 years is 15%.

7%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Hubei Jumpcan Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's operating income is 11%. The projected CAGR for the next 2 years is 2%.

11%
Past Growth
2%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Hubei Jumpcan Pharmaceutical Co Ltd

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's net income is 13%. The projected CAGR for the next 2 years is 15%.

13%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Hubei Jumpcan Pharmaceutical Co Ltd's stock price target?
Price Target
53.41 CNY

According to Wall Street analysts, the average 1-year price target for Hubei Jumpcan Pharmaceutical Co Ltd is 53.41 CNY with a low forecast of 52.88 CNY and a high forecast of 54.98 CNY.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's revenue is 7%. The projected CAGR for the next 2 years is 15%.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
2%

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's operating income is 11%. The projected CAGR for the next 2 years is 2%.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
15%

For the last 8 years the compound annual growth rate for Hubei Jumpcan Pharmaceutical Co Ltd's net income is 13%. The projected CAGR for the next 2 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 252,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.